Edition:
United States

Grifols SA (GRLS.MC)

GRLS.MC on Madrid SE C.A.T.S.

16.75EUR
7 Dec 2016
Change (% chg)

-- (--)
Prev Close
€16.75
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
710,897
52-wk High
€22.45
52-wk Low
€16.70

GRLS.MC

Chart for GRLS.MC

About

Grifols SA is a Spain-based company engaged in the biopharmaceuticals manufacture. The Company’s activities are divided into four business segments: Bioscience, Hospital, Diagnostic and Raw materials. The Bioscience division focuses on the research, development, manufacturing and marketing of products derived from human plasma... (more)

Overall

Beta: 0.13
Market Cap(Mil.): €10,879.18
Shares Outstanding(Mil.): 687.55
Dividend: 0.18
Yield (%): 1.84

Financials

  GRLS.MC Industry Sector
P/E (TTM): 32.81 30.14 30.77
EPS (TTM): 0.52 -- --
ROI: 6.37 15.85 15.23
ROE: 15.96 16.96 16.56

BRIEF-Grifols 9-month net profit rises to 406.1 mln euros

* 9-month net profit 406.1 million euros ($448.5 million)versus 401.6 million euros year ago

Nov 08 2016

BRIEF-Oncbiomune signs term sheet to acquire Vitel Laboratorios, S.A. De C.V.

* Oncbiomune signs term sheet to acquire Vitel Laboratorios, s.a. De c.v. Source text for Eikon: Further company coverage:

Nov 03 2016

BRIEF-Grifols to pay FY 2016 interim dividend of 0.18 euro/shr

* Says to pay interim dividend for 2016 of 0.18 euro ($0.1972) per share on Dec. 7 Source text for Eikon: Further company coverage: ($1 = 0.9127 euros) (Gdynia Newsroom)

Oct 31 2016

BRIEF-Medica Sur receives green light to buy LMP

* Said on Wednesday received an approval from a competition watchdog to acquire Laboratorio Medico Polanco (LMP) and its units Laboratorios Clinicos de Puebla (LCP), Laboratorios Clinicosde Puebla en Bioequivalencia (LCPB) and other units

Oct 06 2016

BRIEF-Prim buys branches from Laboratorios Milo for fixed price of 1.2 mln euros

* Buys pharmacy, orthopedics and podiatry branches from Laboratorios Milo for 1.24 million euros ($1.39 million) and variable price depending on results of the branches in 2016-2020 Source text for Eikon:

Sep 12 2016

BRIEF-Grifols' phase I Alzheimer vaccine study shows good safety profile, tolerability

* Says unit Araclon Biotech presents phase I Alzheimer vaccine results showing good safety profile and tolerability

Aug 01 2016

BRIEF-Grifols reports H1 EBITDA at 553.6 mln euros

* H1 net profit 264.4 million euros ($293.1 million) versus 256 million euros in Reuters poll

Jul 28 2016

BRIEF-Grifols to buy a 48,000 square meter plot of land

* To buy a plot of 48,716 square meters to expand its production facilities in Barcelona

Jul 22 2016

Swiss stocks - Factors to watch on July 7

ZURICH, July 7 The Swiss blue-chip SMI was seen opening 0.3 percent higher at 7,921 points on Thursday, according to premarket indications by bank Julius Baer .

Jul 07 2016

BRIEF-SGS buying Laboratorios Contecon Urbar

* Says it's buying Laboratorios Contecon Urbar with operations in Colombia and Panama.

Jul 07 2016

Earnings vs. Estimates